CLINICAL TRIALS

As the breadth of PH research expands, PHA is committed to keeping its members informed about ongoing clinical research pertaining to evaluation and treatment of pulmonary hypertension. One mechanism to achieve this is to provide institutions and other research sponsors who are conducting multi-center clinical trials with an opportunity to describe relevant studies.

Trial Name: Targeting the Right Ventricle in Pulmonary HypertensionSponsoring Institution: University of PennsylvaniaPosted February 21, 2014Read More

Trial Name: Trial of the Early Combination of Oral Treprostinil With a PDE-5 Inhibitor or ERA in Subjects wth Pulmonary Arterial HypertensionSponsoring Institution: United Theraputics CorporationPosted August 27, 2013Read More

Trial Name: A Natural History Study of Novel Biomarkers in Pulmonary Arterial HypertensionSponsoring Institution: National Institutes of HealthPosted January 22, 2013Read more

Trial Name: A Pilot Study of the Effect of Spironolactone Therapy on Exercise Capacity and Endothelial Dysfunction in Pulmonary Arterial HypertensionSponsoring Institution: National Institutes of HealthPosted January 22, 2013Read more

Trial Name: A Multiple Ascending Dose Study of Tadalafil to Assess the Pharmacokinetics and Safety in a Pediatric Population with Pulmonary Arterial HypertensionSponsoring Institution: Eli Lilly and CompanyPosted July 6, 2012Read more

Trial Name: An open-label study to explore the impact of inhaled trepostinil sodium on ventilation perfusion matching when used for treatment of group 1 pulmonary arterial hypertension in patients with concomitant chronic obstructive pulmonary disease (COPD)Sponsoring Institution: United TherapeuticsPosted April 13, 2012Read more

Email Updates

The information provided on the PHA website is provided for general information only. It is not intended as legal, medical or other professional advice, and should not be relied upon as a substitute for consultations with qualified professionals who are familiar with your individual needs.